Explore MOTS-C/Humanin blend dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. Real-world mitochondrial-derived peptide blend mixing data.
The MOTS-C/Humanin blend pairs the two best-characterized mitochondrial-derived peptides into a single pre-mixed reconstitution. This data shows the combined dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when working with this multi-MDP protocol.
The MOTS-C / Humanin blend pairs the two most-characterized members of the mitochondrial-derived peptide (MDP) family into a single pre-mixed reconstitution. The two molecules share an unusual molecular origin — both are short peptides encoded by small open reading frames within the mitochondrial ribosomal RNA genes, a finding that overturned the long-standing assumption that mitochondrial DNA encoded only the 13 known electron-transport-chain proteins. Humanin was the first of the family to be discovered, identified by Hashimoto et al. (PNAS 2001) from a cDNA-library screen of an Alzheimer's-disease brain searching for neuroprotective factors; it is a 24-amino-acid peptide encoded within the 16S rRNA region of the mitochondrial genome. MOTS-c followed roughly fifteen years later — Lee et al.
The MOTS-C/Humanin Blend combines two mitochondrial-derived peptides — MOTS-c and humanin — in one research product, most often sourced for metabolic and cellular-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone MOTS-c and Humanin entries for full per-component pharmacology.
The combination has no blend-specific mechanism in the published literature; each component acts through its own established pathway. MOTS-c activates AMPK and modulates the folate-methionine cycle; humanin binds intracellular Bax to inhibit apoptosis and signals extracellularly through CNTFR/WSX-1/gp130 to activate STAT3. The blend is a convenience formulation, not a fixed-ratio combination with documented synergy.
No peer-reviewed clinical or pre-clinical study has evaluated this specific blend or its dose ratio. The single-component literature for MOTS-c (metabolic, insulin-sensitivity, healthspan) and humanin (neuroprotection, anti-apoptotic, insulin-sensitivity) is reviewed in their respective entries. No registered ClinicalTrials.gov trial exists for any MDP blend.
MOTS-C/Humanin Blend has a reported half-life of ~4 hours (MOTS-c-driven), and the dose intervals researchers model most often fall around weekly. Both mitochondrial peptides clear within hours, so neither builds up between weekly doses; the downstream metabolic effects are thought to outlast the plasma exposure. MOTS-C/Humanin Blend is a blend of Humanin and MOTS-c, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Anti-Aging Peptides on WPA.
67 MOTS-C/Humanin Blend reconstitution calculations have been logged by the WPA community. The most common dose entered is 5mg (15 calculations). The median dose across all sessions is 1mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (46 sessions). The most common dosing frequency is daily (7x/week) (4 logged protocols), followed by 3x/week (4).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.